Related Experiment Video
Updated: Jul 31, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Treatment of Restenosis
Mario Togni1, Stephan Windecker, Bernhard Meier
1Swiss Cardiovascular Center Bern, University Hospital, 3010 Bern, Switzerland. bernhard.meier@insel.ch
Current Interventional Cardiology Reports
|November 7, 2001
Summary
Restenosis, a complication of coronary interventions, often recurs after repeat angioplasty. Prevention strategies, including intracoronary brachytherapy and drug-eluting stents, are crucial for managing in-stent restenosis.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Biology
Background:
- Restenosis remains a significant challenge following percutaneous coronary intervention (PCI).
- In-stent restenosis (ISR) presents a more complex treatment scenario.
- Current treatments for diffuse ISR lack proven efficacy.
Purpose of the Study:
- To review the challenges and emerging strategies for managing restenosis after PCI.
- To highlight the need for preventative measures against restenosis.
Main Methods:
- Literature review of restenosis treatment and prevention strategies.
- Analysis of outcomes for repeat balloon angioplasty and stent implantation in ISR.
- Evaluation of novel preventative therapies.
Main Results:
- Repeat angioplasty for restenosis has a recurrence rate of 32-37%.
- Focal ISR in large vessels may benefit from stenting.
- Efficacy of debulking techniques for diffuse ISR is unproven.
Conclusions:
- Preventing restenosis is paramount due to limitations of repeat interventions.
- Intracoronary brachytherapy and drug-eluting stents show promise in preventing restenosis.
- Further research is needed to optimize ISR management.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:26Aneurysm III: Interprofessional Care
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...